Advanced search
Publication Cover
Expert Review of Vaccines Volume 5, 2006 - Issue 1
Submit an article Journal homepage
289
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Immunotherapy and the development of cancer vaccines

Angus G Dalgleish St George’s University of London, Dept. of Oncology, Cranmer Terrace, London, SW17 0RE, UK
Pages 1-4 | Published online: 09 Jan 2014

References

  • Dalgleish AG. Cancer vaccines as a therapeutic strategy. Expert Rev. Vaccines 3(6), 665–668 (2004).
  • Jocham D, Richter A, Hoffmann et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363(9409), 594–599 (2004).
  • Vermorken JB, Claessen AM, Van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150), 345–350 (1999).
  • Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res. 6(4), 299–306 (1996).
  • Souberbielle BE, Westby M, Ganz S et al. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther. 5(11), 1447–1454 (1998).
  • Hrouda D, Todryksm, Perry MJ et al. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int. 86(6), 742–748 (2000).
  • Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11(12), 4469–4478 (2005).
  • Arlen PM, Gulley JL, Todd N et al. Anti-androgen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 174(2), 539–546 (2005).
  • Maraveyas A, Babau B, Kennard D et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. Oncol. 10(7), 817–824 (1999).
  • O’Brien ME, Anderson E, Kaukel E et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann. Oncol. 15(6), 906–914 (2004).
  • Assersohn L, Souberbielle BE, O’Brien ME et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 14(1), 23–27 (2002).
  • Whelan M, Ball G, Beattie C, Dalgleish A, Biomarkers for the development of cancer vaccines. Pers.Med. 3(1), (2006) (In Press).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.